Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02044250|
Recruitment Status : Completed
First Posted : January 23, 2014
Last Update Posted : April 14, 2021
Seoul National University Hospital
Chong Kun Dang Pharmaceutical
Samjin Pharmaceutical Co., Ltd.
Daewoong Pharmaceutical Co. LTD.
Hanmi Pharmaceutical co., ltd.
Information provided by (Responsible Party):
Hyo-Soo Kim, Seoul National University Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||August 2020|
|Actual Study Completion Date :||March 2021|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, Rha SW, Bae JW, Lee NH, Hur SH, Yoon J, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Han JK, Shin ES, Kim HS; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021 Jun 26;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Epub 2021 May 16.